CEBP Translational Cancer Medicine 2008: Cancer Clinical Trials and Personalized Medicine
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Cell Growth & Differentiation
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Cerhan, J. R.
Right arrow Articles by Folsom, A. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Cerhan, J. R.
Right arrow Articles by Folsom, A. R.
Cancer Epidemiology Biomarkers & Prevention Vol. 11, 1466-1471, November 2002
© 2002 American Association for Cancer Research

Hormone Replacement Therapy and Risk of Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia1

James R. Cerhan2, Celine M. Vachon, Thomas M. Habermann, Steven M. Ansell, Thomas E. Witzig, Paul J. Kurtin, Carol A. Janney, Wei Zheng, John D. Potter, Thomas A. Sellers and Aaron R. Folsom

Departments of Health Sciences Research [J. R. C., C. M. V., C. A. J., T. A. S.], Hematology [T. M. H. S. M. A., T. E. W.], and Laboratory Medicine and Pathology [P. J. K.], Mayo Clinic, Rochester, Minnesota 55905; Department of Health Services Research, Vanderbilt University Medical Center, Nashville, Tennessee 37232 [W. Z.]; Cancer Prevention Research Program, Fred Hutchinson Cancer Research Center, Seattle, Washington 98104 [J. D. P.]; and Division of Epidemiology, University of Minnesota School of Public Health, Minneapolis, Minnesota 55454 [A. R. F.]


   Abstract
Top
 Abstract
Introduction
 Subjects and Methods
 Results
 Discussion
 References
 
Our objective in this study was to evaluate whether the useof hormone replacement therapy (HRT) is associated with non-Hodgkin lymphoma (NHL) or chronic lymphocytic leukemia (CLL). A cohort of 37,220 Iowa women ages 55 to 69 years in 1986 with no history of prior cancer was linked annually to a population-based cancer registry. Through 1998 (13 years of follow-up), 258 incident cases of NHL were identified, including 135 cases of diffuse NHL, 58 cases of follicular NHL, and 31 cases of small lymphocytic NHL. In addition, 63 cases of CLL were identified. Current and former use of HRT (primarily estrogen) and other cancer risk factors were self-reported on the baseline (1986) questionnaire. Compared with never users of HRT at study baseline, current [multivariate relative risk (RR), 1.4; 95% confidence intervals (CIs), 0.9–2.0) but not former (RR, 1.1; 95% CI, 0.8–1.4) users were at increased risk of NHL after adjustment for age and other confounding factors. This association was seen only in nodal NHL [RRcurrent, 1.5 (95% CI, 1.0–2.4); RRformer, 1.1 (95% CI, 0.8–1.6)] and was not apparent for extra-nodal sites. Of the common subtypes, there was a strong positive association with follicular NHL [RRcurrent, 3.3 (95% CI, 1.6–6.9); RRformer, 2.6 (95% CI, 1.4–4.7)], and women who were current users for more than 5 years had the highest risk (RR, 3.9; 95% CI, 1.8–8.6). There was no association with diffuse or small lymphocytic NHL, or with CLL. Most of the follicular NHLs were nodal (88%), and exclusion of extra-nodal sites slightly strengthened the association with HRT. For diffuse NHL, 64% of the cases were nodal, and there was no association of HRT with either nodal or extra-nodal sites. These data suggest that HRT is a risk factor for follicular NHL but not for diffuse or small lymphocyte NHL or CLL.


   Introduction
Top
 Abstract
 Introduction
Subjects and Methods
 Results
 Discussion
 References
 
HRT3 is classified as a Group 1 carcinogen by the IARC based on both animal and human data (1) . Estrogen is also known to have immunomodulatory effects (2) , and NHL is a tumor the development of which is sensitive to immunological function (3) . Animal studies have clearly shown that estrogen administration induces endometrial, breast, and ovarian tumors, and there are data showing that s.c. estrogen can also induce lymphoma (4) . In humans, HRT is associated with a substantially increased risk of endometrial cancer (when estrogen is unopposed by progestins) and a moderately elevated risk of breast cancer (5) . HRT also appears to be associated with a reduced risk of colorectal cancer, whereas data for ovarian, liver, and thyroid cancer as well as cutaneous melanoma are equivocal or show no association (5) .

There are few data regarding HRT and NHL. A case-control study reported a positive association of estrogen replacement therapy and NHL (6) , whereas another case-control study of intermediate and high grade NHL found a weak inverse association that was not statistically significant (7) . The early results (7-year follow-up) from the Iowa Women’s Health Study cohort found no association with HRT use (8) . We now report more extended follow-up of the Iowa cohort (13 years and nearly double the number of cases). In addition, we report results for common NHL subtypes as well as for CLL, which is currently considered to be part of the spectrum of NHL (9) .


   Subjects and Methods
Top
 Abstract
 Introduction
 Subjects and Methods
Results
 Discussion
 References
 
The Iowa Women’s Health Study Cohort.
This study was reviewed and approved by the institutional review boards at the University of Iowa and the University of Minnesota. Details on the Iowa Women’s Health Study design specific to NHL and CLL have been published previously (8 , 10) . Briefly, in January 1986, a mailed questionnaire was returned by 41,836 randomly selected women who were ages 55–69 years and had a valid Iowa driver’s license in 1985 (42.7% response rate). There were only minor demographic differences between respondents and nonrespondents to the baseline survey (11) and, compared with nonrespondents, respondents have had somewhat lower cancer incidence and mortality rates for smoking-related cancers (12) .

The baseline questionnaire inquired about current and past HRT, reproductive history, anthropometrics, and dietary and other lifestyle factors. HRT was determined by the following questions: "Have you ever used pills other than birth control pills which contain estrogen or other female hormones (e.g., at the change of life or menopause, after surgery, or at any other time)?" Response categories were "yes, currently," "yes, but not currently," and "never." Subjects responding yes were then asked "How long did you take estrogens or other female hormone pills (other than birth control pills)?" Response categories for duration of use were "one month or less," "2–6 months," "7–12 months," "13 months-2 years," "3–5 years," or "more than 5 years." Names and doses of pills were not obtained.

Cohort Follow-Up.
Vital status and cancer incidence in the cohort was ascertained through 13 years of follow-up (1986–1998). Follow-up questionnaires were mailed in 1987, 1989, 1992, and 1997 to ascertain vital status and address changes. Deaths were also ascertained by annual linkage to Iowa death-certificate data, supplemented by linkage to the National Death Index for survey nonrespondents and emigrants from Iowa. Out migration has been estimated at 1%/year.

Cancer incidence, except for nonmelanoma skin cancer, was ascertained by annual linkage to the Iowa Cancer Registry, part of the National Cancer Institute’s SEER program (13) . All of the participants were linked by a combination of social security number; first, last, and maiden names, birth date, and postal (ZIP) code. The Iowa Cancer Registry collects cancer data, including identifying information, tumor site, morphology, histological grade, and extent of disease, on all persons who were Iowa residents at the time of their diagnosis. All of the tumor site and morphology data were derived from pathology reports of the diagnosing pathologist, and there was no centralized review of the tumor material.

Topographic and morphological data were coded using the ICD-O, second edition (14) , which is based on the Working Formulation (15) . The histological subtypes of NHL were grouped according to Groves et al. (16) into the following subtypes: small lymphocytic, follicular, diffuse, high grade, and peripheral T-cell (ICD-O codes given in Table 1Citation ). This system is a slight modification of the Working Formulation for use in epidemiological studies. In addition, the primary site was classified as nodal (lymph nodes, tonsil, and spleen) or extranodal (all other sites that are not primary lymphoid organs) according to the ICD-O definition (14) . CLL (ICD-O morphology code 9823) was also analyzed, but as a distinct end point (i.e., it was not aggregated with small lymphocytic NHL).


View this table:
[in this window]
[in a new window]
  		Table 1 Distribution of primary site and subtype of 258 incident NHLs, Iowa Women’s Health Study, 1986–1998

 
Data Analysis.
Before data analysis, we excluded women with a self-reported history of cancer or cancer chemotherapy on the baseline (1986) questionnaire (n = 3,902) to provide a cancer-free at-risk cohort. We further excluded women who were premenopausal (n = 545), had missing data on the HRT question (n = 167), or who had their diagnosis at or before the date of return of their questionnaire (n = 2). This left a final cohort of 37,220 available for analysis. Each woman accumulated person-years of follow-up from the date of receipt of the 1986 baseline questionnaire until the date of NHL diagnosis, date of emigration from Iowa, or date of death; if none of these events occurred, person-years were accumulated through December 31, 1998.

Age-adjusted and multivariate RRs, along with 95% CIs, were calculated as measures of association between HRT and NHL incidence, and were estimated using Cox proportional hazards regression (17) . Other risk factors for NHL in this dataset, including age, marital status, farm residence (18) , transfusion history (8) , adult-onset diabetes (8) , alcohol use (19) , cigarette smoking (20) , and red meat and fruit intake (21) were included in the multivariate models as potential confounders. Although not associated with the risk of NHL in this cohort, in additional models, we adjusted for education and age at menopause (22) .


   Results
Top
 Abstract
 Introduction
 Subjects and Methods
 Results
Discussion
 References
 
The mean age of the 37,220 women in the at-risk cohort was 61.7 years, and more than 99% were white. During 441,409 person-years of follow-up (1986–1998), 258 women developed NHL. The mean age at diagnosis was 69.7 years (range, 57–81 years). Approximately 70% of the NHL cases were nodal, and of the extra-nodal sites, the stomach was the most common (Table 1)Citation . The most common NHL subtype was diffuse NHL (52%), followed by follicular (23%) and small lymphocytic (12%) NHL; only 9% of the cases could not be subclassified.

Characteristics of women who used HRT are provided in Table 2Citation . Compared with never users of HRT, current users, on average, were slightly younger, had a lower body mass index, and consumed fewer servings of red meat. They were also more likely to have higher educational attainment, to be currently married, to have ever had a blood transfusion, to have used oral contraceptives, and to drink alcohol, whereas they were less likely to have a history of adult-onset diabetes. However, the differences across groups were generally small. There were few notable differences in smoking history or the proportion living on a farm.


View this table:
[in this window]
[in a new window]
  		Table 2 Relationship between use of HRT and selected NHL risk factors at study baseline (1986), Iowa Women’s Health Study

 
As shown in Table 3Citation , compared with never users of HRT at baseline, the incidence of NHL was slightly elevated in former users (RR, 1.1) and somewhat more elevated in current users (RR, 1.4), although neither estimate was statistically significant. When evaluated by duration of use, the greatest risk of NHL was for current users at baseline with <=5 years of use (RR, 1.6); RRs in the other categories were <=1.2. None of these estimates was statistically significant, and adjustment for major NHL risk factors in these data did not alter these estimates.


View this table:
[in this window]
[in a new window]
  		Table 3 Age and multivariatea RRs and 95% CIs of NHL (all, subtypes) and CLL in relation to use of HRT, Iowa Women’s Health Study, 1986–1998

 
With respect to anatomical site, there was a statistically significant positive association with current HRT use and the risk of nodal NHL (RR, 1.6), which changed little after multivariate adjustment (RR, 1.5). Again, elevated risk was mainly among current users with <=5 years of use (RRmultivariate, 2.1). There was essentially no association of HRT with extra-nodal NHL.

We next evaluated common subtypes of NHL. For follicular NHL, risk was elevated in former (RR, 2.7) and current users (RR, 3.3), and this was not attenuated in multivariate adjustment. When evaluated by the duration of use, risk was generally higher with longer use, and the highest risk was seen for current users of >5 years (RR, 3.9). Most (88%) of the follicular NHLs were nodal. When we analyzed only nodal follicular NHL, the multivariate association with former (RR, 2.7; 95% CI; 1.4–5.1) and current (RR, 3.7; 95% CI; 1.7–8.0) HRT use strengthened slightly.

Of the other common subtypes of NHL, there was no consistent association of HRT use with the risk of diffuse NHL, small lymphocytic NHL, or CLL. An analyses of duration of use revealed no consistent trends. Of the diffuse NHLs, 64% were nodal. There was no association between HRT use and the risk of either diffuse nodal [(RRcurrent, 1.0 (95% CI 0.5–2.1); RRformer, 0.9 (95% CI, 0.5–1.4)]] or diffuse extra-nodal [RRcurrent, 1.0 (95% CI, 0.4–2.6); RRformer, 1.0 (95% CI, 0.4–2.6] NHL.

In all of the multivariate models, additional adjustment for education and age at menopause did not alter the risk estimates (data not shown).


   Discussion
Top
 Abstract
 Introduction
 Subjects and Methods
 Results
 Discussion
References
 
We found a weak positive association between current use of HRT and the risk of NHL overall. Among the common subtypes, HRT use was associated with follicular NHL, particularly nodal follicular NHL, but not with diffuse or small lymphocytic NHL nor with CLL. Longer duration of use was associated with a greater risk of follicular NHL among both former and current HRT users, and the association with follicular NHL was not confounded by several key demographic, medical history, lifestyle, or dietary risk factors.

Strengths of this study include the prospective cohort study design in a well-defined, community-based population, case ascertainment using a SEER cancer registry, inclusion of the full spectrum of NHL cases (i.e., aggressive cases that often do not get enrolled into case-control studies), and virtually complete follow-up of the cohort. Limitations include an abbreviated assessment of HRT based on self-report, including no data on the type of preparation used, nor precise length of use. However, even with the limited HRT assessment used in the study, HRT use was inversely associated with total and coronary heart disease mortality, colon cancer incidence, and hip fracture, and was positively associated with endometrial and breast cancer incidence (23) . On the basis of other data collected around the time of the baseline survey, Folsom et al. (23) have estimated that no more than 20% of the current users, and a smaller proportion of former users, were also using a progestin in combination with estrogen. Thus, the issue of combination therapy and the risk of NHL remains open.

Other limitations of this study include relatively small sample sizes for some subtypes, and the lack of data on other subtypes of potential interest (e.g., mantle cell lymphoma; MALT lymphoma; high-grade lymphoma; peripheral T-cell lymphomas). Subtype classification relied on reports from the local pathologist, and there was no central review of the cases. In addition, our classification of subtypes relied on the SEER ICD-O second-edition codes, which are based on the Working Formulation; however, this does not necessarily translate into the more current WHO Classification system (9) . In particular, the diffuse lymphomas are likely to include some lymphomas of T-cell origin, as well as other more uniquely defined subtypes. However, follicular NHL appears to be reliably classified by pathologists (24) , and this subtype has seen little modification with adoption of the revised European-American lymphoma (REAL) classification (25) and WHO systems (9) . In addition, we based our subtype categorization on the recent summary data, which suggests that these are reasonable groupings of the SEER data for etiological epidemiology studies (16) .

Besides the early results form this cohort (8) , which showed no association with the risk of NHL, only two other studies have addressed the association of HRT and NHL. Bernstein and Ross (6) published preliminary results from a population-based case-control study (n = 337 female cases and matched controls) conducted from 1979 to 1982 in Los Angeles. Compared with women who had never used estrogen replacement therapy, women who had ever used it were at a slightly increased risk of NHL (OR, 1.29; 95% CI, 0.94–1.79), mainly attributable to women who had used it 13 or more months (OR, 1.58; 95% CI, 1.09–2.29). These estimates were not adjusted for other risk factors, and the distribution of cases by subtypes (or a subtype analysis) was not reported. In a case-control study of intermediate- and high-grade B-cell NHL, conducted in Los Angeles from 1989 to 1992 (7) , ever use of HRT was inversely associated with risk (OR, 0.60) among HIV-negative women, although this estimate was not statistically significant (95% CI, 0.31–1.18). Additional adjustment for age at menopause did not alter this association. The proportion of intermediate to high-grade cases was not reported; therefore, we cannot directly compare these results with our data. In our study, the use of HRT for >5 years among both former and current users was associated with RRs of <1 for diffuse NHL (all intermediate grade), although the estimates were based on small numbers and lacked precision. Thus, the association of HRT with intermediate- and high-grade NHL remains unresolved at this time. To our knowledge, no prior study has evaluated HRT use and the risk of follicular or small lymphocytic NHL or CLL.

Correlates of endogenous estrogen, including reproductive (22 , 26, 27, 28, 29) and menstrual history (22) factors, have not shown a consistent association with NHL in the few studies to evaluate these associations. No data are currently published evaluating these factors with specific subtypes of NHL.

Although we cannot rule out the possibility that the specific association of HRT use with follicular NHL may be a chance finding, this association is supported by several lines of evidence. Overall, the incidence rate of NHL is about 50% higher in men than women (in both Iowa and in the United States), and this is true for nearly all subtypes except follicular NHL, for which the rates are approximately equal (13) . In Iowa from 1978 to 1997, the age-incidence curve for follicular NHL among women is similar to that seen for female breast cancer (Fig. 1)Citation , in contrast to the age-incidence curves for diffuse, small lymphocytic leukemia and CLL (which continue to increase rapidly with age) or high-grade NHL (which shows neither pattern; Fig. 2Citation ). These patterns are similar for all SEER data for white females for 1993–1997. The age-incidence pattern for female breast cancer (which follicular NHL follows) has been widely interpreted as suggesting a role for ovarian hormones in this malignancy (30) .



View larger version (19K):
[in this window]
[in a new window]
  		Fig. 1. Age-incidence curves for breast cancer, follicular NHL, and all NHL excluding follicular NHL, Iowa women, 1978–1997 (source: SEER program; Ref. 13 ).

 


View larger version (23K):
[in this window]
[in a new window]
  		Fig. 2. Age-incidence curves for follicular NHL, diffuse NHL, small lymphocytic NHL, high-grade NHL, and CLL, Iowa Women, 1978–1997 (source: SEER program; Ref. 13 ).

 
Evaluation of ovarian hormones (particularly estrogen) in the etiology of NHL generally, or follicular NHL specifically, is limited. However, estrogen clearly plays a role in immunological function (31, 32, 33, 34, 35) , and immunological function is thought to be important in lymphomagenesis (3) . For example, estrogen is known to influence lymphopoiesis, Th1/Th2 balance, antigen presentation, lymphocyte homing, and cytokine production (2 , 33) . Estrogen at physiological levels is considered to be immunostimulatory, in part by increasing Th1 cytokine production (e.g., secretion of IL-2, IFN-{gamma}, and tumor necrosis factor ß), which is associated with an augmentation of the cellular immune system and the suppression of the humoral immune system. At higher concentrations (e.g., in pregnancy), there is a shift toward Th2 cytokine production (e.g., secretion of IL-4, IL-5, IL-6, and IL-10), which is associated with the suppression of the cellular immune system and stimulation of humoral immunity (33 , 36 , 37) . However, the exact roles and mechanisms of estrogen in the immune system are not completely understood (2) , in part because estrogen effects vary between sexes and across species (32) , and even across strains of mice (38) . Even less is known about the role of estrogen in lymphomagenesis. Both estrogen-receptor-mediated and non-receptor-mediated mechanisms may be relevant (39 , 40) .

In conclusion, we found a weak positive association of HRT with NHL overall, and a strong positive association for follicular NHL, particularly for nodal follicular NHL. The association with follicular NHL is novel, and requires replication. Future studies should assess HRT formulation and duration of use and should classify cases by the current WHO system (9) . Further research on the role of estrogen in the development and progression of NHL, and follicular NHL in particular, may lead to new insights into the etiology and treatment of this disease.


   Footnotes
 
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

1 Supported in part by the National Cancer Institute Grant R01 CA39741 (to The Iowa Women’s Health Study). J. R. C. was supported in part by a National Cancer Institute Preventive Oncology Award (K07 CA64220). Back

2 To whom requests for reprints should be addressed, at Department of Health Sciences Research, Mayo Clinic, 200 First Street SW, Rochester, MN 55905. Phone: (507) 538-0499; Fax: (507)266-2478; E-mail: cerhan.james{at}mayo.edu Back

3 The abbreviations used are: HRT, hormone replacement therapy; NHL, non-Hodgkin lymphoma; CLL, chronic lymphocytic leukemia; SEER, Surveillance, Epidemiology and End Results; ICD-O, International Classification of Diseases for Oncology; RR, relative risk; CI, confidence interval; OR, odds ratio; IL, interleukin. Back

Received 2/ 4/02; revised 7/26/02; accepted 8/29/02.


   References
Top
 Abstract
 Introduction
 Subjects and Methods
 Results
 Discussion
 References
 

  1. IARC. . Hormonal contraception and post-menopausal hormone therapy., IARC Lyon, France 1999.
  2. Olsen N. J., Kovacs W. J. Gonadal steroids and immunity. Endocr. Rev., 17: 369-384, 1996.[Medline]
  3. Hoover R. N. Lymphoma risks in populations with altered immunity: a search for a mechanism. Cancer Res., 52: 5477s-5478s, 1992.[Medline]
  4. Li J. J. Perspectives in hormonal carcinogenesis: animal models to human disease. Prog. Clin. Biol. Res., 394: 447-454, 1996.[Medline]
  5. Beral V., Banks E., Reeves G., Appleby P. Use of HRT and the subsequent risk of cancer. J. Epidemiol. Biostat., 4: 191-210, 1999.[Medline]
  6. Bernstein L., Ross R. K. Prior medication use and health history as risk factors for non-Hodgkin’s lymphoma: preliminary results from a case-control study in Los Angeles County. Cancer Res., 52: 5510s-5515s, 1992.[Medline]
  7. Nelson R. A., Levine A. M., Bernstein L. Reproductive factors and risk of intermediate- or high-grade B-Cell non-Hodgkin’s lymphoma in women. J. Clin. Oncol., 19: 1381-1387, 2001.[Abstract/Free Full Text]
  8. Cerhan J. R., Wallace R. B., Folsom A. R., Potter J. D., Sellers T. A., Zheng W., Lutz C. T. Medical history risk factors for non-Hodgkin’s lymphoma in older women. J. Natl. Cancer Inst. (Bethesda), 89: 314-318, 1997.[Abstract]
  9. Harris N. L., Jaffe E. S., Diebold J., Flandrin G., Muller-Hermelink H. K., Vardiman J., Lister T. A., Bloomfield C. D. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House. Virginia, November 1997. J. Clin. Oncol., 17: 3835-3849, 1999.[Abstract/Free Full Text]
  10. Cerhan J. R., Wallace R. B., Dick F., Kemp J., Parker A. S., Zheng W., Sellers T. A., Folsom A. R. Blood transfusion and risk of non-Hodgkin lymphoma subtypes and chronic lymphocytic leukemia. Cancer Epidemiol. Biomark. Prev., 10: 361-368, 2001.[Abstract/Free Full Text]
  11. Folsom A. R., Kaye S. A., Prineas R. J., Potter J. D., Gapstur S. M., Wallace R. B. Increased incidence of carcinoma of the breast associated with abdominal adiposity in postmenopausal women. Am. J. Epidemiol., 131: 794-803, 1990.[Abstract/Free Full Text]
  12. Bisgard K. M., Folsom A. R., Hong C. P., Sellers T. A. Mortality and cancer rates in nonrespondents to a prospective cohort study of older women: 5-year follow-up. Am. J. Epidemiol., 139: 990-1000, 1994.[Abstract/Free Full Text]
  13. Ries L. A. G., Kosary C. L., Hankey B. F., Miller B. A., Clegg L. X. SEER Cancer Statistics Review, 1973–1996, NIH Pub. 99-2789 National Cancer Institute Bethesda, MD 1999.
  14. Percy C., Van Holten V., Muir C. . International classification of diseases for oncology, Ed. 2 World Health Organization Geneva 1990.
  15. Percy C., O’Conor G., Ries L., Jaffe E. Non-Hodgkin’s lymphoma: application of the international classification of diseases for oncology (ICD-O) to the working formulation. Cancer (Phila.), 54: 1435-1438, 1984.[Medline]
  16. Groves F. D., Linet M. S., Travis L. B., Devesa S. S. Cancer surveillance series: non-Hodgkin’s lymphoma incidence by histologic subtype in the United States from 1978 through 1995. J. Natl. Cancer Inst., 92: 1240-1251, 2000.[Abstract/Free Full Text]
  17. Cox D. R. Regression models and life tables (with discussion). J. R. Stat. Soc. B, 34: 187-220, 1972.
  18. Folsom A. R., Zhang S., Sellers T. A., Zheng W., Kushi L. H., Cerhan J. R. Cancer incidence among women living on farms: findings from the Iowa Women’s Health Study. J. Occup. Environ. Med., 38: 1171-1176, 1996.[Medline]
  19. Chiu B. C., Cerhan J. R., Gapstur S. M., Sellers T. A., Zheng W., Lutz C. T., Wallace R. B., Potter J. D. Alcohol consumption and non-Hodgkin lymphoma in a cohort of older women. Br. J. Cancer, 80: 1476-1482, 1999.[Medline]
  20. Parker A. S., Cerhan J. R., Dick F., Kemp J., Habermann T. M., Wallace R. B., Sellers T. A., Folsom A. R. Smoking and risk of non-Hodgkin’s lymphoma subtypes in a cohort of older Iowa women. Leuk. Lymphoma, 37: 341-349, 2000.[Medline]
  21. Chiu B. C., Cerhan J. R., Folsom A. R., Sellers T. A., Kushi L. H., Wallace R. B., Zheng W., Potter J. D. Diet and risk of non-Hodgkin lymphoma in older women. J. Am. Med. Assoc., 275: 1315-1321, 1996.[Abstract]
  22. Cerhan J. R., Habermann T. M., Vachon C. M., Putnam S. D., Zheng W., Potter J. D., Folsom A. R. Menstrual and reproductive factors and risk of non-Hodgkin lymphoma: the Iowa Women’s Health Study. Cancer Causes Control, 13: 131-136, 2002.[Medline]
  23. Folsom A. R., Mink P. J., Sellers T. A., Hong C. P., Zheng W., Potter J. D. Hormonal replacement therapy and morbidity and mortality in a prospective study of postmenopausal women. Am. J. Public Health, 85: 1128-1132, 1995.[Medline]
  24. Dick F., VanLier S., Banks P., Frizzera G., Witrak G., Gibson R., Everett G., Schuman L., Isacson P., O’Conor G., Cantor K., Blattner W., Blair A. Use of the working formulation for non-Hodgkin’s lymphoma in epidemiologic studies: agreement between reported diagnoses and a panel of experienced pathologists. J. Natl. Cancer Inst., 78: 1137-1144, 1987.
  25. Herrinton L. J. Epidemiology of the revised European-American lymphoma classification subtypes. Epidemiol. Rev., 20: 187-203, 1998.[Free Full Text]
  26. Miller A. B., Barclay T. H., Choi N. W., Grace M. G., Wall C., Plante M., Howe G. R., Cinader B., Davis F. G. A study of cancer, parity and age at first pregnancy. J. Chronic Dis., 33: 595-605, 1980.[Medline]
  27. Olsson H., Landin Olsson M., Ranstam J. Late age at first full-term pregnancy as a risk factor for women with malignant lymphoma. Neoplasma, 37: 185-190, 1990.[Medline]
  28. Tavani A., Pregnolato A., La Vecchia C., Franceschi S. A case-control study of reproductive factors and risk of lymphomas and myelomas. Leuk. Res., 21: 885-888, 1997.[Medline]
  29. Adami H.-O., Tsaih S.-W., Lambe M., Hseih C.-C., Adami J., Trichopoulos D., Melbye M., Glimelius B. Pregnancy and risk of non-Hodgkin’s lymphoma: A prospective study. Int. J. Cancer, 70: 155-158, 1997.[Medline]
  30. Henderson B. E., Pike M. C., Bernstein L., Ross R. K. Breast cancer Schottenfeld D. Fraumeni J. F., Jr. eds. . Cancer Epidemiology and Prevention, 1022-1039, Oxford University Press New York 1996.
  31. Forsberg J. G. Short-term and long-term effects of estrogen on lymphoid tissues and lymphoid cells with some remarks on the significance for carcinogenesis. Arch. Toxicol., 55: 79-90, 1984.[Medline]
  32. Yung R. L. Mechanisms of lupus: the role of estrogens. Clin. Exp. Rheumatol., 17: 271-275, 1999.[Medline]
  33. Whitacre C. C., Reingold S. C., O’Looney P. A., Task Force on Gender Multiple Sclerosis and Autoimmunity. A gender gap in autoimmunity. Science (Wash. DC), 283: 1277-1278, 1999.[Free Full Text]
  34. Giltay E. J., Fonk J. C., von Blomberg B. M., Drexhage H. A., Schalkwijk C., Gooren L. J. In vivo effects of sex steroids on lymphocyte responsiveness and immunoglobulin levels in humans. J. Clin. Endocrinol. Metab., 85: 1648-1657, 2000.[Abstract/Free Full Text]
  35. Kincade P. W., Medina K. L., Payne K. J., Rossi M. I., Tudor K. S., Yamashita Y., Kouro T. Early B-lymphocyte precursors and their regulation by sex steroids. Immunol. Rev., 175: 128-137, 2000.[Medline]
  36. Cutolo M., Sulli A., Seriolo B., Accardo S., Masi A. T. Estrogens, the immune response and autoimmunity. Clin. Exp. Rheumatol., 13: 217-226, 1995.[Medline]
  37. Malarkey W. B., Burleson M., Cacioppo J. T., Poehlmann K., Glaser R., Kiecolt-Glaser J. K. Differential effects of estrogen and medroxyprogesterone on basal and stress-induced growth hormone release. IGF-1 levels, and cellular immunity in postmenopausal women. Endocrine, 7: 227-233, 1997.[Medline]
  38. Nilsson N., Carlsten H. Estrogen induces suppression of natural killer cell cytotoxicity and augmentation of polyclonal B cell activation. Cell. Immunol., 158: 131-139, 1994.[Medline]
  39. Danel L., Menouni M., Cohen J. H., Magaud J. P., Lenoir G., Revillard J. P., Saez S. Distribution of androgen and estrogen receptors among lymphoid and haemopoietic cell lines. Leuk. Res., 9: 1373-1378, 1985.[Medline]
  40. Kawatsu R., Ezaki T., Kotani M., Akagi M. Growth-promoting effect of oestriol in a lymphoma lacking oestrogen receptors. Br. J. Cancer, 59: 563-568, 1989.[Medline]



This article has been cited by other articles:


Home page
 Ann OncolHome page
G. Corrao, A. Zambon, V. Conti, F. Nicotra, C. La Vecchia, C. Fornari, G. Cesana, P. Contiero, G. Tagliabue, R. E. Nappi, et al.
Menopause hormone replacement therapy and cancer risk: an Italian record linkage investigation
Ann. Onc., January 1, 2008; 19(1): 150 - 155.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Epidemiol. Biomarkers Prev.Home page
O. Landgren, Y. Zhang, S. H. Zahm, P. Inskip, T. Zheng, and D. Baris
Risk of Multiple Myeloma following Medication Use and Medical Conditions: A Case-Control Study in Connecticut Women
Cancer Epidemiol. Biomarkers Prev., December 1, 2006; 15(12): 2342 - 2347.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
G. L. Bond, K. M. Hirshfield, T. Kirchhoff, G. Alexe, E. E. Bond, H. Robins, F. Bartel, H. Taubert, P. Wuerl, W. Hait, et al.
MDM2 SNP309 Accelerates Tumor Formation in a Gender-Specific and Hormone-Dependent Manner.
Cancer Res., May 15, 2006; 66(10): 5104 - 5110.
[Abstract] [Full Text] [PDF]

Home page
 Am J EpidemiolHome page
E. T. Chang, K. E. Smedby, H. Hjalgrim, C. Schollkopf, A. Porwit-MacDonald, C. Sundstrom, E. Tani, F. d'Amore, M. Melbye, H.-O. Adami, et al.
Medication Use and Risk of Non-Hodgkin's Lymphoma
Am. J. Epidemiol., November 15, 2005; 162(10): 965 - 974.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Epidemiol. Biomarkers Prev.Home page
C. F. Skibola, P. M. Bracci, R. A. Paynter, M. S. Forrest, L. Agana, T. Woodage, K. Guegler, M. T. Smith, and E. A. Holly
Polymorphisms and Haplotypes in the Cytochrome P450 17A1, Prolactin, and Catechol-O-Methyltransferase Genes and Non-Hodgkin Lymphoma Risk
Cancer Epidemiol. Biomarkers Prev., October 1, 2005; 14(10): 2391 - 2401.
[Abstract] [Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
E. T. Chang, H. Hjalgrim, K. E. Smedby, M. Akerman, E. Tani, H. E. Johnsen, B. Glimelius, H.-O. Adami, and M. Melbye
Body Mass Index and Risk of Malignant Lymphoma in Scandinavian Men and Women
J Natl Cancer Inst, February 2, 2005; 97(3): 210 - 218.
[Abstract] [Full Text] [PDF]

Home page
 Am J EpidemiolHome page
S. L. Glaser, C. A. Clarke, R. A. Nugent, C. B. Stearns, and R. F. Dorfman
Reproductive Factors in Hodgkin's Disease in Women
Am. J. Epidemiol., September 15, 2003; 158(6): 553 - 563.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Cerhan, J. R.
Right arrow Articles by Folsom, A. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Cerhan, J. R.
Right arrow Articles by Folsom, A. R.

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Cell Growth & Differentiation